Vendor scorecard

Juniper (Australia)

65/100
Routable
Australia · Telehealth · Eucalyptus brand · women's-health focused · GLP-1 + lifestyle bundle ($300-500/mo); brand-pharmacy sourced (Mounjaro / Ozempic)

Juniper (Australia) scored 65/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.

11-signal breakdown
  • COA on every lot
    Brand pharmacy supply via TGA-registered partners
    80
  • Cold-chain verified
    75
  • Rx legality
    TGA-licensed; AHPRA-registered prescribers. Sept 2025 TGA infringement notices (advertising-related, not supply-related) created compliance overhang; ad practices revised post-November 2025 TGA guidance update
    70
  • Compound identity
    Brand-only formulary · no compounded GLP-1 in AU at scale
    80
  • Dose accuracy
    80
  • Endotoxin testing
    Brand manufacturing standard
    75
  • Refund posture
    65
  • Channel clarity
    Bundled-pricing structure ($300-500/mo) wraps Rx in the program · transparent post-November 2025 ad-guidance update; pre-update advertising drew TGA scrutiny
    65
  • Support quality
    Health-coaching component differentiates from pure-Rx telehealth
    75
  • Price transparency
    Bundle pricing published; medication portion vs program portion not always cleanly separated
    65
  • Longitudinal retention
    Eucalyptus group revenue ~A$120.9M FY2024-25 (55% YoY) shows real scale; Sept 2025 TGA enforcement is recent overhang but has not affected supply or operations
    60
Supply where Juniper (Australia) operates
Mounjaro
Stable

TGA-approved for T2D, off-label weight prescribing legal. Juniper / Eucalyptus / Hub Health all stocking; no reported gaps.

1w ago
Ozempic
Stable

Recovered from the severe 2023-24 shortage that prioritised T2D patients over weight-only access.

1w ago
Wegovy
Tight

August 2024 launch eased the pressure, but Wegovy supply remains tighter than tirzepatide.

1w ago
How we score

The 11-signal rubric is public.

Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.

If Juniper (Australia) wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.

Want a match for your situation?

Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.